ENO1 Knockdown Impedes Tumour Progression and Promotes Oxidative Phosphorylation in Cutaneous Squamous Cell Carcinoma
DOI:
https://doi.org/10.2340/actadv.v105.43849Keywords:
ENO1, glycolysis, oxidative phosphorylation, skin neoplasms, Akt/mTORAbstract
Cutaneous squamous cell carcinoma (cSCC) is a common skin malignancy characterized by aggressive growth and metabolic reprogramming. Alpha-enolase (ENO1), a key glycolytic enzyme that is frequently over-expressed in cancer, has not been thoroughly investigated in cSCC, particularly with regard to how it coordinates glycolysis and oxidative phosphorylation (OXPHOS). ENO1 expression was interrogated in Gene Expression Omnibus datasets and validated in cSCC patient specimens. ENO1 was silenced in cSCC cell lines, and the resulting effects on cell viability, migration, invasion, apoptosis, and reactive oxygen species (ROS) levels were quantified. The impact of ENO1 knockdown on tumour growth was assessed in a xenograft model. Metabolic flux was analysed with Seahorse XFe96 extracellular-flux assays. ENO1 was significantly elevated in cSCC relative to normal skin and correlated positively with proliferative and invasive markers, but negatively with apoptosis markers. ENO1 silencing curtailed cell viability, migration, and invasion, while inducing apoptosis. Additionally, tumour growth was significantly impaired in vivo. Seahorse analysis showed that ENO1 knockdown suppressed glycolysis and redirected metabolic flux toward OXPHOS. Consistent with this shift, intracellular ROS increased and partially suppressed cell viability by modulating the ROS-sensitive Akt/mTOR pathway. In conclusion, ENO1 knockdown compromises tumorigenicity and promotes OXPHOS. Combining ENO1 inhibition with oxidative-stress-enhancing treatments, such as chemotherapy or radiotherapy, may further enhance efficacy.
Downloads
References
Quadri M, Marconi A, Sandhu SK, Kiss A, Efimova T, Palazzo E. Investigating cutaneous squamous cell carcinoma in vitro and in vivo: novel 3D tools and animal models. Front Med (Lausanne) 2022; 9: 875517. DOI: https://doi.org/10.3389/fmed.2022.875517
Levine DE, Karia PS, Schmults CD. Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study. JAMA Dermatol 2015; 151: 1220–1225. DOI: https://doi.org/10.1001/jamadermatol.2015.1702
Kang HJ, Jung SK, Kim SJ, Chung SJ. Structure of human alpha-enolase (hENO1), a multifunctional glycolytic enzyme. Acta Crystallogr D Biol Crystallogr 2008; 64: 651–657. DOI: https://doi.org/10.1107/S0907444908008561
Jiang P, Du W, Wu M. Regulation of the pentose phosphate pathway in cancer. Protein Cell 2014; 5: 592–602. DOI: https://doi.org/10.1007/s13238-014-0082-8
Sun L, Lu T, Tian K, Zhou D, Yuan J, Wang X, et al. Alpha-enolase promotes gastric cancer cell proliferation and metastasis via regulating AKT signaling pathway. Eur J Pharmacol 2019; 845: 8–15. DOI: https://doi.org/10.1016/j.ejphar.2018.12.035
Capello M, Ferri-Borgogno S, Riganti C, Chattaragada MS, Principe M, Roux C, et al. Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget 2016; 7: 5598–5612. DOI: https://doi.org/10.18632/oncotarget.6798
Dai J, Zhou Q, Chen J, Rexius-Hall ML, Rehman J, Zhou G. Alpha-enolase regulates the malignant phenotype of pulmonary artery smooth muscle cells via the AMPK-Akt pathway. Nat Commun 2018; 9: 3850. DOI: https://doi.org/10.1038/s41467-018-06376-x
Zhan P, Zhao S, Yan H, Yin C, Xiao Y, Wang Y, et al. Alpha-enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer. Mol Carcinog 2017; 56: 1427–1437.
White-Al Habeeb NM, Di Meo A, Scorilas A, Rotondo F, Masui O, Seivwright A, et al. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma. Clin Exp Metastasis 2015; 32: 531–541. DOI: https://doi.org/10.1007/s10585-015-9725-2
Ejeskar K, Krona C, Caren H, Zaibak F, Li L, Martinsson T, et al. Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death. BMC Cancer 2005; 5: 161. DOI: https://doi.org/10.1186/1471-2407-5-161
Garcia-Diez I, Hernandez-Munoz I, Hernandez-Ruiz E, Nonell L, Puigdecanet E, Bodalo-Torruella M, et al. Transcriptome and cytogenetic profiling analysis of matched in situ/invasive cutaneous squamous cell carcinomas from immunocompetent patients. Genes Chromosomes Cancer 2019; 58: 164–174. DOI: https://doi.org/10.1002/gcc.22712
Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Toriseva M, Kivisaari A, et al. EphB2 promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol 2015; 135: 1882–1892. DOI: https://doi.org/10.1038/jid.2015.104
Lambert SR, Mladkova N, Gulati A, Hamoudi R, Purdie K, Cerio R, et al. Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. Br J Cancer 2014; 110: 520–529. DOI: https://doi.org/10.1038/bjc.2013.760
Wang S, Zhang X, Lei H, Song L, Huang Y, Kang T, et al. Proline-rich 11 (PRR11) promotes the progression of cutaneous squamous cell carcinoma by activating the EGFR signaling pathway. Mol Carcinog 2023; 62: 613–627. DOI: https://doi.org/10.1002/mc.23510
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545–15550. DOI: https://doi.org/10.1073/pnas.0506580102
Ma S, Wang N, Liu R, Zhang R, Dang H, Wang Y, et al. ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase. J Exp Clin Cancer Res 2021; 40: 387. DOI: https://doi.org/10.1186/s13046-021-02195-z
Nolfi-Donegan D, Braganza A, Shiva S. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol 2020; 37: 101674. DOI: https://doi.org/10.1016/j.redox.2020.101674
Chen S, Zhang Y, Wang H, Zeng YY, Li Z, Li ML, et al. WW domain-binding protein 2 acts as an oncogene by modulating the activity of the glycolytic enzyme ENO1 in glioma. Cell Death Dis 2018; 9: 347. DOI: https://doi.org/10.1038/s41419-018-0376-5
Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong SW, et al. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol 2015; 8: 22. DOI: https://doi.org/10.1186/s13045-015-0117-5
Zhan P, Zhao S, Yan H, Yin C, Xiao Y, Wang Y, et al. α-enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer. Mol Carcinog 2017; 56: 1427–1437. DOI: https://doi.org/10.1002/mc.22603
Ji M, Wang Z, Chen J, Gu L, Chen M, Ding Y, et al. Up-regulated ENO1 promotes the bladder cancer cell growth and proliferation via regulating beta-catenin. Biosci Rep 2019; 39: BSR20190503. DOI: https://doi.org/10.1042/BSR20190503
Li Y, Li Y, Luo J, Fu X, Liu P, Liu S, et al. FAM126A interacted with ENO1 mediates proliferation and metastasis in pancreatic cancer via PI3K/AKT signaling pathway. Cell Death Discov 2022; 8: 248. DOI: https://doi.org/10.1038/s41420-022-01047-9
Song Y, Luo Q, Long H, Hu Z, Que T, Zhang X, et al. Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Mol Cancer 2014; 13: 65. DOI: https://doi.org/10.1186/1476-4598-13-65
Masoud R, Reyes-Castellanos G, Lac S, Garcia J, Dou S, Shintu L, et al. Targeting mitochondrial Complex I overcomes chemoresistance in high OXPHOS pancreatic cancer. Cell Rep Med 2020; 1: 100143. DOI: https://doi.org/10.1016/j.xcrm.2020.100143
Noble RA, Thomas H, Zhao Y, Herendi L, Howarth R, Dragoni I, et al. Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma. Br J Cancer 2022; 127: 937–947. DOI: https://doi.org/10.1038/s41416-022-01848-w
Kumar PR, Moore JA, Bowles KM, Rushworth SA, Moncrieff MD. Mitochondrial oxidative phosphorylation in cutaneous melanoma. Br J Cancer 2021; 124: 115–123. DOI: https://doi.org/10.1038/s41416-020-01159-y
Wang Y, Ou L, Li X, Zheng T, Zhu WP, Li P, et al. The mitochondrial RNA polymerase POLRMT promotes skin squamous cell carcinoma cell growth. Cell Death Discov 2022; 8: 347. DOI: https://doi.org/10.1038/s41420-022-01148-5
Shiratori R, Furuichi K, Yamaguchi M, Miyazaki N, Aoki H, Chibana H, et al. Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner. Sci Rep 2019; 9: 18699. DOI: https://doi.org/10.1038/s41598-019-55296-3
Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 2015; 162: 540–551. DOI: https://doi.org/10.1016/j.cell.2015.07.016
Kuznetsov AV, Javadov S, Margreiter R, Grimm M, Hagenbuchner J, Ausserlechner MJ. Structural and functional remodeling of mitochondria as an adaptive response to energy deprivation. Biochim Biophys Acta Bioenerg 2021; 1862: 148393. DOI: https://doi.org/10.1016/j.bbabio.2021.148393
Kuang Y, Han X, Xu M, Yang Q. Oxaloacetate induces apoptosis in HepG2 cells via inhibition of glycolysis. Cancer Med 2018; 7: 1416–1429. DOI: https://doi.org/10.1002/cam4.1410
Lu CL, Qin L, Liu HC, Candas D, Fan M, Li JJ. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition: a Warburg-reversing effect. PLoS One 2015; 10: e0121046. DOI: https://doi.org/10.1371/journal.pone.0121046
Cheung EC, Vousden KH. The role of ROS in tumour development and progression. Nat Rev Cancer 2022; 22: 280–297. DOI: https://doi.org/10.1038/s41568-021-00435-0
Toshniwal AG, Gupta S, Mandal L, Mandal S. ROS inhibits cell growth by regulating 4EBP and S6K, independent of TOR, during development. Dev Cell 2019; 49: 473–489 e479. DOI: https://doi.org/10.1016/j.devcel.2019.04.008
Zhao Y, Hu X, Liu Y, Dong S, Wen Z, He W, et al. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer 2017; 16: 79. DOI: https://doi.org/10.1186/s12943-017-0648-1
Liu Z, Huang M, Hong Y, Wang S, Xu Y, Zhong C, et al. Isovalerylspiramycin I suppresses non-small cell lung carcinoma growth through ROS-mediated inhibition of PI3K/AKT signaling pathway. Int J Biol Sci 2022; 18: 3714–3730. DOI: https://doi.org/10.7150/ijbs.69989
Liang W, He X, Bi J, Hu T, Sun Y. Role of reactive oxygen species in tumors based on the ‘seed and soil’ theory: a complex interaction (Review). Oncol Rep 2021; 46. DOI: https://doi.org/10.3892/or.2021.8159
Hambright HG, Meng P, Kumar AP, Ghosh R. Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. Oncotarget 2015; 6: 7195–7208. DOI: https://doi.org/10.18632/oncotarget.3131
Xu Z, Feng J, Li Y, Guan D, Chen H, Zhai X, et al. The vicious cycle between ferritinophagy and ROS production triggered EMT inhibition of gastric cancer cells was through p53/AKT/mTor path-way. Chem Biol Interact 2020; 328: 109196. DOI: https://doi.org/10.1016/j.cbi.2020.109196
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Liumei Song, Sharui Ma, Shengbang Wang, Xiu Zhang, Wenxin Fan, Ning Wang, Shuo Feng, Qiqi Duan, Ruimin Bai, Yan Zheng
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
